Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

Fusing research and manufacturing, the hub aims to challenge Asian dominance, showing that pharmaceutical sovereignty lies as much in global supply chains as in lab capacity ...

Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...